EWSR1 and neoplasm: Direct drug targeting of EWS-FLI1 is challenging given the lack of catalytic activity, hence pathways that are dependent on the function of EWS-FLI1 have been suggested as an alternative approach that could confer synthetic lethal and hence tumour-specific targeting.